88 related articles for article (PubMed ID: 2782888)
1. [Clinical efficacy of intratumoral administration of BRM in advanced cancer and their mechanism of actions].
Kuninobu H; Toge T; Takayama T; Baba N; Kegoya Y; Yanagawa E
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2769-73. PubMed ID: 2782888
[TBL] [Abstract][Full Text] [Related]
2. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
3. [The metastatic tumor and immunotherapy].
Fuchimoto S; Orita K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1260-5. PubMed ID: 2730024
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
Homma S; Sagawa Y; Komita H; Koido S; Nagasaki E; Ryoma Y; Okamoto M
Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of BRM in skin cancer].
Ishihara K
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1603-8. PubMed ID: 3382232
[TBL] [Abstract][Full Text] [Related]
6. Antimetastatic effect of biological response modifiers in the "double grafted tumor system".
Ebina T; Kohya H; Yamaguchi T; Ishida N
Jpn J Cancer Res; 1986 Oct; 77(10):1034-42. PubMed ID: 3096919
[TBL] [Abstract][Full Text] [Related]
7. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
9. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
10. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
11. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation and consideration of BRM-BRM and HDP (host defense potentiators)].
Chihara G
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1588-96. PubMed ID: 3382231
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
[TBL] [Abstract][Full Text] [Related]
14. [On the behalf of the Japanese Society of Biological Response Modifiers].
Ishihara K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):906-11. PubMed ID: 2730029
[TBL] [Abstract][Full Text] [Related]
15. [Immunological effects of locoregional immunochemotherapy for liver metastases of gastric cancer].
Sugiyama Y; Kato M; Takao H; Kida H; Kunieda K; Umemoto T; Miya K; Azuma S; Furuta T; Saji S
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1461-4. PubMed ID: 8373205
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy of intratumoral OK-432 administration in advanced cancer patients.
Toge T; Kuninobu H; Yamaguchi Y; Baba N; Kegoya Y; Hattori T
Jpn J Surg; 1988 Nov; 18(6):668-74. PubMed ID: 3266768
[TBL] [Abstract][Full Text] [Related]
17. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
Pak AS; Ip G; Wright MA; Young MR
Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
[TBL] [Abstract][Full Text] [Related]
18. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
19. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
20. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
